When measured in cohorts of patients with NSCLC and SpA, two diseases that have been associated with FAP and high tissue turnover, we saw that C3F was significantly elevated compared to healthy controls, suggesting a potential use for the biomarker across disease with FAP activity. Here, FAP is linked to non-small cell lung carcinoma.